

Research Article

Integrated Bioinformatics Analysis for Identifying the Significant Genes as Poor Prognostic Markers in Gastric Adenocarcinoma

Yamei Li ¹, Yan Luo,² Qiang Tian,² Yu Lai,³ Lei Xu,² Hailong Yun,² Yang Liang,² Dandan Liao,² Rui Gu,⁴ Liye Liu,⁵ Mu Yuan,⁶ Yijiao Li,⁷ Yufan Li,⁴ Mingze Lu,⁸ Xin Yong,⁹ and Hua Zhang ^{2,10}

¹Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu 610041, China

²Department of Pathology, General Hospital of Western Theater Command, Chengdu 610083, China

³Department of Oncology, The Fifth People's Hospital of Nanchong (People's Hospital of Gaoping District Nanchong), Nanchong 637000, China

⁴Laboratory of Basic Medicine, General Hospital of Western Theater Command, Chengdu 610083, China

⁵Department of General Surgery, General Hospital of Western Theater Command, Chengdu 610083, China

⁶Department of Scientific Research & Training, General Hospital of Western Theater Command, Chengdu 610083, China

⁷Department of Anesthesiology, The People's Hospital of Leshan, Leshan 614000, China

⁸Department of Human Resources, General Hospital of Western Theater Command, Chengdu 610083, China

⁹Department of Gastroenterology, General Hospital of Western Theater Command, Chengdu 610083, China

¹⁰State Key Laboratory of Biotherapy, Sichuan University, Chengdu 610041, China

Correspondence should be addressed to Hua Zhang; zh1217104734@qq.com

Received 12 January 2022; Revised 8 May 2022; Accepted 18 May 2022; Published 11 June 2022

Academic Editor: Faisal Raza

Copyright © 2022 Yamei Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gastric adenocarcinoma (GAC) is the most common histological type of gastric cancer and imposes a considerable health burden globally. The purpose of this study was to identify significant genes and key pathways participated in the initiation and progression of GAC. Four datasets (GSE13911, GSE19826, GSE54129, and GSE79973) including 171 GAC and 77 normal tissues from Gene Expression Omnibus (GEO) database were collected and analyzed. Through integrated bioinformatics analysis, we obtained 69 commonly differentially expressed genes (DEGs) among the four datasets, including 20 upregulated and 49 downregulated genes. The prime module in protein-protein interaction network of DEGs, including ADAMTS2, COL10A1, COL1A1, COL1A2, COL8A1, BGN, and SPP1, was enriched in protein digestion and absorption, ECM-receptor interaction, focal adhesion, PI3K-Akt signaling pathway, and amoebiasis. Furthermore, expression and survival analysis found that all seven hub genes were highly expressed in GAC tissues and 6 of them (except for SPP1) were able to predict poor prognosis of GAC. Finally, we verified the 6 high-expressed hub genes in GAC tissues via immunohistochemistry, Western blot, and RNA quantification analysis. Altogether, we identified six significantly upregulated DEGs as poor prognostic markers in GAC based on integrated bioinformatical methods, which could be potential molecular markers and therapeutic targets for GAC patients.

1. Introduction

Gastric adenocarcinoma (GAC), the predominant histological type of gastric cancer, is the fifth most common cancer ranked after lung, breast, colorectal, and prostate cancers [1, 2]. GAC, also known as stomach adenocarcinoma (STAD), has increased more than 1,000,000 new cases and led to deaths of more than 768,000 people worldwide in 2020

[3]. Although improvements in endoscopic, surgical, and systemic treatments have been made for decades, the mortality rate of GAC is still high and the global 5-year survival rates remain unsatisfactory [1, 4]. Thus, GAC still imposes a considerable health burden globally.

Although the global 5-year survival rates are relatively low, the rates in Japan and South Korea are far more optimistic [5, 6], owing to early detection and screening efforts

in these Asian countries [7]. Furthermore, it is reported that the 5-year survival rate of early-stage T1 GAC (according to the TNM classification of malignant tumors) is ~95%, while advanced-stage GAC (which cannot be surgically treated) has a median survival of ~9-10 months [8, 9], which further emphasizes the critical importance of early detection and diagnosis.

Molecular markers are vital for early detection of cancer [10–12]. To date, several biomarkers have been used for the diagnosis and determination of the clinical stage of GAC. Among them, carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and erb-b2 receptor tyrosine kinase 2 (HER2) are the most frequently used biomarkers for GAC in clinical setting [13, 14]. However, due to the insufficient specificity and sensitivity of the current markers, novel specific and sensitive molecular markers are still on urgent demand, especially in the field of early diagnosis and prognosis [13–15]. Bioinformatics analysis is a powerful and comprehensive tool for analyzing gene expression data from multiple datasets, which is perfect for excavating the potential molecular markers laid in Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) datasets. Therefore, in the current study, we mainly focused on exploring the commonly differential expressed genes among different GEO datasets. Gene ontology (GO) and KEGG enrichment analysis were further conducted to identify the hub genes and key pathways enriched in the commonly DEGs. Protein-protein interaction (PPI) network of the DEGs was constructed, and core genes were determined via the Cytoscape Molecular Complex Detection (MCODE). In addition, DAVID, GEPIA, and Kaplan–Meier plotter were applied to re-analyze the expression and survival information of the core genes, respectively [16, 17]. Finally, immunohistochemistry, Western blot, and RNA quantification analysis were performed to validate the expressions of the identified genes in GAC tissue samples.

2. Materials and Methods

2.1. Microarray Data Information. NCBI-GEO is a free public database and provides us with gene expression profile of numerous cancers. The following criteria were used to screen the datasets and ensure relevant data were recorded: (I) the sample includes gastric adenocarcinoma and normal tissues; (II) the study type is expression profiling by array; (III) the species is limited to Homo sapiens; (IV) access to raw data is allowed. We obtained the gene expression profiles of GSE13911, GSE19826, GSE54129, and GSE79973 in gastric adenocarcinoma and paired normal tissues. Microarray data of GSE13911, GSE19826, GSE54129, and GSE79973 were all on account of GPL570 platforms ([HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array) which included a total of 171 GAC tissues and 77 normal tissues.

2.2. DEGs Identification. Background correction and normalization were conducted through robust multi-array average (RMA) and Microarray Suite (MAS) approach. The

GEO2R online tools [18] were used to identify DEGs between the GAC specimen and normal specimen with $|\log_2FC| > 2$ and an adjusted P value < 0.05 [16–18]. Then, the raw data were analyzed in Venn software online to identify the commonly DEGs among the original four datasets. The DEGs with $\log_2FC > 0$ were considered as upregulated genes, while the DEGs with $\log_2FC < 0$ were considered as downregulated genes [16, 17].

2.3. GO and Pathway Enrichment Analysis. The functions and pathways enrichment of candidate DEGs were analyzed using DAVID (the Database for Annotation, Visualization and Integrated Discovery, <https://david.ncifcrf.gov/>) [19], which is an online bioinformatic tool with the function of integrating the GO and pathway enrichment analysis [20, 21]. Through DAVID, we identified the unique biological properties of the commonly DEGs and visualized the DEGs enrichment of molecular function (MF), cellular component (CC), biological process (BP), and Kyoto Encyclopedia of Gene and Genome (KEGG) pathways ($P < 0.05$) [16, 17].

2.4. Integration of PPI Network and Modular Analysis. STRING (Search Tool for the Retrieval of Interacting Genes, <https://cn.string-db.org/>) online tool [22] was used to evaluate the PPI information of DEGs. Then, the STRING app in Cytoscape [23] was employed to examine the potential correlation between these DEGs (maximum number of interactors = 0 and confidence score ≥ 0.4). In addition, the MCODE app in Cytoscape was used to identify the modules and hub genes of the PPI network (degree cutoff = 2, max. depth = 100, k -core = 2, and node score cutoff = 0.2) [16, 17]. PPI network properties, such as node degree and betweenness centrality, were visualized by shape size and label font size, respectively.

2.5. Survival and RNA Sequencing Expression Analysis. Kaplan–Meier plotter is a common website tool (<https://kmplot.com/>), which contains considerable information among several cancers, including breast and gastric cancer [24]. The survival analysis was conducted by Kaplan–Meier plotter, and the log rank P value and hazard ratio (HR) with 95% confidence intervals were computed and shown on the plot. To validate these DEGs with significant expression pattern, we applied the GEPIA (Gene Expression Profiling Interactive Analysis, <https://gepia.cancer-pku.cn/>) website to analyze the data of RNA sequencing expression based on the GTEx projects and TCGA datasets [25].

2.6. Immunohistochemical (IHC) Staining. IHC staining was performed to detect the protein level of certain genes in GAC and normal human tissue samples and performed according to the standard protocols using following antibodies: anti-ADAMTS2 (bs-5858R, 1:500), anti-COL10A1 (BA2023, 1:400), anti-COL1A1 (BA0325, 1:400), anti-COL1A2 (BM4017, 1:100), anti-COL8A1 (bs-7529R, 1:500), and anti-BGN (bs-7552R, 1:500).

2.7. Western Blot. GAC and adjacent normal tissue samples were grinded and lysed with RIPA buffer supplemented with protease inhibitor cocktail. Protein concentrations of the extracts were measured with BCA assay. The Western blot analysis was performed according to the standard protocols using the above antibodies.

2.8. RNA Quantification. Total RNA was extracted from GAC and adjacent normal tissues with TRIzol reagent (Invitrogen) and reverse-transcribed using PrimeScript™ RT reagent kit (Takara). Quantitative real-time PCR analysis was performed on LightCycler (Roche) with TB Green® Premix Ex Taq™ II (Takara). Data were normalized to GAPDH expression. The primers used for real-time PCR were as follows: GAPDH (forward: 5'-GGA GCG AGA TCC CTC CAA AAT-3', reverse: 5'-GGC TGT TGT CAT ACT TCT CAT GG-3'), ADAMTS2 (forward: 5'-GTG CAT GTG GTG TAT CGC C-3', reverse: 5'-AGG ACC TCG ATG TTG TAG TCA-3'), COL10A1 (forward: 5'-CAT AAA AGG CCC ACT ACC CAA C-3', reverse: 5'-ACC TTG CTC TCC TCT TAC TGC-3'), COL1A1 (forward: 5'-GAG GGC CAA GAC GAA GAC ATC-3', reverse: 5'-CAG ATC ACG TCA TCG CAC AAC-3'), COL1A2 (forward: 5'-GGC CCT CAA GGT TTC CAA GG-3', reverse: 5'-CAC CCT GTG GTC CAA CAA CTC-3'), COL8A1 (forward: 5'-GCT GCC ACC TCA AAT TCC TC-3', reverse: 5'-CTT TCT TGG GTA CGG CTT CCT-3'), and BGN (forward: 5'-GAG ACC CTG AAT GAA CTC CAC C-3', reverse: 5'-CTC CCG TTC TCG ATC ATC CTG-3').

3. Results

3.1. Identification of DEGs in Gastric Adenocarcinoma. GEO2R online tool was used to determine the DEGs from GSE13911, GSE19826, GSE54129, and GSE79973, which resulted in 484, 388, 971, and 524 DEGs, respectively (Figure 1(a)) ($|\log_2FC| > 2$ and adjust P value < 0.05). Then, the commonly DEGs among the above four datasets were identified by Venn diagram software. Results showed that a total of 69 commonly DEGs were identified, including 20 upregulated genes ($\log_2FC > 2$) and 49 downregulated genes ($\log_2FC < -2$) in GAC tissues (Figures 1(b) and 1(c) and Table 1).

3.2. GO and KEGG Analysis of DEGs in Gastric Adenocarcinoma. In order to examine the biological properties of the 69 DEGs, DAVID software was applied to conduct GO and KEGG analysis. Results of GO analysis indicated that (1) for biological processes (BP), upregulated DEGs were particularly enriched in endodermal cell differentiation, collagen fibril organization, protein heterotrimerization, skin morphogenesis, and cell adhesion, and downregulated DEGs in digestion, potassium ion import, oxidation-reduction process, and bicarbonate transport (Figure 2(a)); (2) for cell component (CC), upregulated DEGs were significantly enriched in extracellular space, collagen trimer, collagen type I trimer, and proteinaceous extracellular matrix, and downregulated DEGs in


extracellular space, lysosome, apical plasma membrane, integral component of plasma membrane, and integral component of membrane (Figure 2(b)); (3) for molecular function (MF), upregulated DEGs were enriched in extracellular matrix structural constituent and heparin binding, and downregulated DEGs in inward rectifier potassium channel activity, hydrogen:potassium-exchanging ATPase activity, and G-protein activated inward rectifier potassium channel activity (Figure 2(c) and Table 2, $P < 0.05$).

Results of KEGG analysis showed that upregulated DEGs were particularly enriched in ECM-receptor interaction, focal adhesion, protein digestion and absorption, PI3K-Akt signaling pathway, amoebiasis, and platelet activation (Figure 3(a)), while downregulated DEGs in gastric acid secretion, retinol metabolism, chemical carcinogenesis, collecting duct acid secretion, glycolysis/gluconeogenesis, drug metabolism-cytochrome P450, metabolism of xenobiotics by cytochrome P450, and metabolic pathways (Figure 3(b) and Table 3, $P < 0.05$).


3.3. PPI Network and Modular Analysis of DEGs. The DEGs PPI network complex was constructed via Cytoscape software. Results showed that 44 DEGs including 16 upregulated and 28 downregulated genes were enrolled, and 75 edges were formed (Figure 4(a)). There were 25 DEGs which were not included into the DEGs PPI network. Then, we applied Cytoscape MCODE to further analyze the prime module and ADAMTS2, COL10A1, COL1A1, COL1A2, COL8A1, BGN, and SPP1 were identified among the 44 nodes. Results also showed that the above seven hub nodes were all upregulated genes (Figure 4(b)).

3.4. Re-Analysis of Seven Hub Genes by KEGG Pathway Enrichment. To further understand the possible enriched pathways of the seven hub DEGs, KEGG pathway enrichment was re-analyzed via DAVID. Results showed that seven core genes were significantly enriched in several cancer-related pathways. In detail, COL1A2, COL1A1, and COL10A1 were enriched in protein digestion and absorption; COL1A2, COL1A1, and SPP1 were enriched in ECM-receptor interaction, focal adhesion, and PI3K-Akt signaling pathway; COL1A2 and COL1A1 were further enriched in amoebiasis (Figure 5 and Table 4, $P < 0.05$).


3.5. Analysis of Hub Genes via the GEPIA and Kaplan–Meier Plotter. To further validate the significance of the seven central genes, GEPIA and Kaplan–Meier plotter online tools were utilized to identify the expression data and survival data, respectively. GEPIA expression data showed that all seven hub genes were highly expressed in GAC tissues compared to normal tissues (Figure 6 and Table 5, $P < 0.05$). Kaplan–Meier plotter survival data showed that high expression of ADAMTS2, COL10A1, COL1A1, COL1A2, COL8A1, and BGN had a significantly worse survival probability, while high expression of SPP1 showed no effect on patient survival (Figure 7 and Table 6, $P < 0.05$).



(a)



(b)



(c)

FIGURE 1: Identification of 69 commonly differentially expressed genes (DEGs) among the four datasets (GSE13911, GSE19826, GSE54129, and GSE79973) through Venn diagram software (available online: <https://bioinformatics.psb.ugent.be/webtools/Venn/>). (a) Volcano plot of DEGs from the four datasets. (b) Twenty DEGs were upregulated among the four datasets ($\log_2FC > 0$). (c) Forty-nine DEGs were downregulated among the four datasets ($\log_2FC < 0$). Different colors represented different datasets in B and C.

TABLE 1: All 69 commonly differentially expressed genes (DEGs) were identified from four profile datasets, including 20 upregulated genes and 49 downregulated genes in the gastric adenocarcinoma tissues compared to normal tissues.

| DEGs | Genes name |
|---------------|--|
| Upregulated | IGF2BP3 SULF1 FAP RARRES1 INHBA SPP1 COL1A1 COL10A1 FNDC1 COL11A1 CEMIP CTHRC1 THBS2 BGN COL1A2 CST1 MFAP2 ADAMTS2 WISP1 COL8A1 |
| Downregulated | CNTN3 LIPF TRIM74//TRIM73 CAPN13 FBP2 AKR1B10 B4GALNT3 CYP2C18 ALDH3A1 ATP4A UGT2B15 KIAA1324 GKN1 ADGRG2 RDH12 GIF CA2 GATA5 ATP4B MAL CAPN9 SLC26A9 ESRRG ADTRP VSTM2A SSTR1 ACER2 MFSD4A DPCR1 ADH7 VSIG1 PGC KCNE2 SOSTDC1 TPCN2 CA9 MUC5AC VSIG2 SPINK7 TMED6 SCNN1B LINC00982 HPGD PSAPL1 CWH43 KCNJ16 KCNJ15 GKN2 CXCL17 |




FIGURE 2: Gene ontology analysis of commonly DEGs in gastric adenocarcinoma. DAVID software was applied to conduct gene ontology. Biological processes (BP) (a), cell component (CC) (b), and molecular function (MF) (c) of the up/downregulated DEGs were shown ($P < 0.05$).

3.6. Validation of the Expression Levels of Six Core Genes in GAC Patients. Finally, we detected the expression levels of the above six genes in GAC specimens and adjacent normal specimens by immunohistochemistry (Figure 8(a)), Western blot (Figure 8(b)), and RNA quantification (Figure 8(c)) analysis. Results showed that ADAMTS2, COL10A1, COL1A1, COL1A2, COL8A1, and BGN were highly expressed in GAC tissues compared to adjacent normal tissues (Figure 8), consistent with the GEPIA expression data.

4. Discussion

Gastric adenocarcinoma is a lethal malignancy cancer. In this study, we applied bioinformatical methods on the basis of four gene expression profile datasets to identify more useful prognostic molecular markers in GAC. A total of 171 GAC specimens and 77 normal specimens were enrolled. First, we revealed a total of 69 commonly DEGs via GEO2R and Venn software ($|\log_2FC| > 2$ and adjust P value < 0.05), including 20 upregulated and 49 downregulated DEGs.

TABLE 2: Gene ontology analysis of differentially expressed genes in gastric adenocarcinoma.

| Expression | Category | Term | Count | % | P-value | FDR |
|------------------|----------------------------|--|-------|----------|----------|----------|
| Upregulated | GOTERM_BP_DIRECT | GO:0035987~endodermal cell differentiation | 3 | 15.0 | 2.41E-04 | 0.277424 |
| | GOTERM_BP_DIRECT | GO:0030199~collagen fibril organization | 3 | 15.0 | 3.59E-04 | 0.413041 |
| | GOTERM_BP_DIRECT | GO:0070208~protein heterotrimerization | 2 | 10.0 | 0.007132 | 7.921921 |
| | GOTERM_BP_DIRECT | GO:0043589~skin morphogenesis | 2 | 10.0 | 0.007132 | 7.921921 |
| | GOTERM_BP_DIRECT | GO:0007155~cell adhesion | 3 | 15.0 | 0.008542 | 9.418433 |
| | GOTERM_CC_DIRECT | GO:0005615~extracellular space | 8 | 40.0 | 4.61E-05 | 0.038561 |
| | GOTERM_CC_DIRECT | GO:0005581~collagen trimer | 3 | 15.0 | 0.001285 | 1.069804 |
| | GOTERM_CC_DIRECT | GO:0005584~collagen type I trimer | 2 | 10.0 | 0.002491 | 2.064654 |
| | GOTERM_CC_DIRECT | GO:0005578~proteinaceous extracellular matrix | 3 | 15.0 | 0.014327 | 11.37209 |
| | GOTERM_MF_DIRECT | GO:0005201~extracellular matrix structural constituent | 3 | 15.0 | 5.25E-04 | 0.415248 |
| GOTERM_MF_DIRECT | GO:0008201~heparin binding | 2 | 10.0 | 0.087398 | 51.56318 | |
| Downregulated | GOTERM_BP_DIRECT | GO:0007586~digestion | 5 | 10.2 | 1.81E-05 | 0.023045 |
| | GOTERM_BP_DIRECT | GO:0010107~potassium ion import | 4 | 8.2 | 4.56E-05 | 0.058116 |
| | GOTERM_BP_DIRECT | GO:0055114~oxidation-reduction process | 7 | 14.3 | 0.003333 | 4.16404 |
| | GOTERM_BP_DIRECT | GO:0015701~bicarbonate transport | 3 | 6.1 | 0.005406 | 6.671731 |
| | GOTERM_CC_DIRECT | GO:0005615~extracellular space | 11 | 22.4 | 0.001646 | 1.61346 |
| | GOTERM_CC_DIRECT | GO:0005764~lysosome | 5 | 10.2 | 0.002499 | 2.44067 |
| | GOTERM_CC_DIRECT | GO:0016324~apical plasma membrane | 5 | 10.2 | 0.006137 | 5.897225 |
| | GOTERM_CC_DIRECT | GO:0005887~integral component of plasma membrane | 10 | 20.4 | 0.008007 | 7.631398 |
| | GOTERM_CC_DIRECT | GO:0016021~integral component of membrane | 22 | 44.9 | 0.009103 | 8.634041 |
| | GOTERM_MF_DIRECT | GO:0005242~inward rectifier potassium channel activity | 3 | 6.1 | 7.31E-04 | 0.820368 |
| | GOTERM_MF_DIRECT | GO:0008900~hydrogen:potassium-exchanging ATPase activity | 2 | 4.1 | 0.00603 | 6.584128 |
| | GOTERM_MF_DIRECT | GO:0015467~G-protein activated inward rectifier potassium channel activity | 2 | 4.1 | 0.019965 | 20.31405 |




FIGURE 3: KEGG analysis of commonly DEGs in gastric adenocarcinoma. KEGG analysis of upregulated DEGs (a) and downregulated DEGs (b) was shown ($P < 0.05$).

TABLE 3: KEGG pathway analysis of differentially expressed genes in gastric adenocarcinoma.

| Expression | Term | Count | % | P-value | Genes |
|-----------------------------|---|-------|----------|--|--|
| Upregulated | ptr04512:ECM-receptor interaction | 5 | 25.0 | 8.56E-07 | COL1A2, COL1A1, THBS2, COL11A1, SPP1 |
| | ptr04510:focal adhesion | 5 | 25.0 | 2.60E-05 | COL1A2, COL1A1, THBS2, COL11A1, SPP1 |
| | ptr04974:protein digestion and absorption | 4 | 20.0 | 5.98E-05 | COL1A2, COL1A1, COL11A1, COL10A1 |
| | ptr04151:PI3K-Akt signaling pathway | 5 | 25.0 | 1.78E-04 | COL1A2, COL1A1, THBS2, COL11A1, SPP1 |
| | ptr05146:amoebiasis | 3 | 15.0 | 0.004694 | COL1A2, COL1A1, COL11A1 |
| | ptr04611:platelet activation | 3 | 15.0 | 0.00728 | COL1A2, COL1A1, COL11A1 |
| Downregulated | hsa04971:gastric acid secretion | 6 | 12.2 | 2.68E-06 | KCNJ16, KCNJ15, ATP4A, ATP4B, KCNE2, CA2 |
| | hsa00830:retinol metabolism | 4 | 8.2 | 0.001043 | RDH12, CYP2C18, ADH7, UGT2B15 |
| | hsa05204:chemical carcinogenesis | 4 | 8.2 | 0.001989 | CYP2C18, ADH7, UGT2B15, ALDH3A1 |
| | hsa04966:collecting duct acid secretion | 3 | 6.1 | 0.003265 | ATP4A, ATP4B, CA2 |
| | hsa00010:glycolysis/gluconeogenesis | 3 | 6.1 | 0.019041 | ADH7, FBP2, ALDH3A1 |
| | hsa00982:drug metabolism—cytochrome P450 | 3 | 6.1 | 0.019581 | ADH7, UGT2B15, ALDH3A1 |
| | hsa00980:metabolism of xenobiotics by cytochrome P450 | 3 | 6.1 | 0.022951 | ADH7, UGT2B15, ALDH3A1 |
| hsa01100:metabolic pathways | 9 | 18.4 | 0.029288 | RDH12, CYP2C18, ACER2, AKR1B10, ADH7, FBP2, UGT2B15, ALDH3A1, LIPF | |




FIGURE 4: DEGs PPI network was constructed by Cytoscape software. (a) There were a total of 44 nodes and 75 edges in the DEGs PPI network complex. The nodes meant proteins; the edges meant the interaction between proteins; red circles meant upregulated DEGs; and green circles meant downregulated DEGs. (b) Modular analysis via Cytoscape software (degree cutoff = 2, max. depth = 100, k -core = 2, and node score cutoff = 0.2). Seven central nodes were screened. Circle size represents node degree, and label font size represents betweenness centrality.




FIGURE 5: KEGG re-analysis of the seven hub genes.

TABLE 4: Re-analysis of seven selected genes via KEGG pathway enrichment.

| Pathway ID | Name | Count | % | P -value | Genes |
|------------|----------------------------------|-------|------|------------|-------------------------|
| cfa04974 | Protein digestion and absorption | 3 | 42.9 | $4.55E-04$ | COL1A2, COL1A1, COL10A1 |
| cfa04512 | ECM-receptor interaction | 3 | 42.9 | $4.89E-04$ | COL1A2, COL1A1, SPP1 |
| cfa04510 | Focal adhesion | 3 | 42.9 | 0.002751 | COL1A2, COL1A1, SPP1 |
| cfa04151 | PI3K-Akt signaling pathway | 3 | 42.9 | 0.00721 | COL1A2, COL1A1, SPP1 |
| cfa05146 | Amoebiasis | 2 | 28.6 | 0.046382 | COL1A2, COL1A1 |

Second, GO and KEGG pathway enrichment analysis showed that 20 upregulated genes enriched in endodermal cell differentiation, protein heterotrimerization, ECM-receptor interaction, focal adhesion, protein digestion and absorption, PI3K-Akt signaling pathway, amoebiasis, and platelet activation, while 49 downregulated genes enriched in digestion, potassium ion import, oxidation-reduction process, bicarbonate transport, inward rectifier potassium channel activity, hydrogen:potassium-exchanging ATPase activity, gastric acid secretion, retinol metabolism, and

metabolic pathways ($P < 0.05$). Third, DEGs PPI network complex of 44 nodes and 75 edges was constructed via Cytoscape software and prime module analysis identified 7 hub genes (ADAMTS2, COL10A1, COL1A1, COL1A2, COL8A1, BGN, and SPP1), which were all upregulated genes and were significantly enriched in several cancer-related pathways. Furthermore, GEPIA analysis showed that all the seven hub genes were highly expressed in GAC tissues ($P < 0.05$). In addition, Kaplan-Meier plotter analysis showed that high expression of ADAMTS2, COL10A1,




FIGURE 6: Expression level of the seven hub genes in gastric adenocarcinoma patients compared to healthy people. To further validate the expression level between GAC patients and normal people, seven genes were analyzed via GEPIA website. All seven genes were significantly highly expressed in GAC specimen compared to normal specimen ($*P < 0.05$). Red color meant GAC tissues ($n = 408$), and grey color meant normal tissues ($n = 211$).

TABLE 5: Validation of seven hub genes via GEPIA.

| Category | Genes |
|--|---|
| Genes with high expression in GAC ($P < 0.05$) | ADAMTS2 COL10A1 COL1A1 COL1A2 COL8A1 BGN SPP1 |

COL1A1, COL1A2, COL8A1, and BGN had a significantly worse survival probability ($P < 0.05$), while SPP1 had no significance ($P > 0.05$). Finally, the 6 highly expressed core genes were validated via immunohistochemistry, Western blot, and RNA quantification analysis in tissue samples. Altogether, we identified six significant upregulated genes as poor prognosis markers in gastric adenocarcinoma via bioinformatical analysis, which could be potential new molecular markers and effective targets for early detection and further research.

The hub genes in the main module of the PPI network of the commonly DEGs are mainly associated with protein digestion and absorption, ECM-receptor interaction, focal adhesion, PI3K-Akt signaling pathway, and amoebiasis. The family of collagen genes (CLO10A1, COL1A1, COL1A2,

etc.) is tightly clustered and participates in the above cancer-related pathways. Furthermore, studies have demonstrated the close relation between collagen genes and gastric adenocarcinoma, including COL10A1, COL1A1, COL1A2, and COL8A1. What's more, it is well known that PI3K-Akt signaling pathway (COL1A2, COL1A1, etc.) plays a vital role in the cell cycle and is activated in various cancers, including GAC [26]. For ADAMTS2, a member of the ADAMTS family is a procollagen N-proteinase [27]. Researches have shown that ADAMTS2 participated in major biological pathways and human disorders [28], but the relation between ADAMTS2 and GAC has rarely been studied [27]. Furthermore, BGN, a key member of the small leucine-rich proteoglycan family, has been shown to participate in many cancers and is associated with poor prognosis in cancer




FIGURE 7: Prognostic information of the seven hub genes. Kaplan–Meier plotter online tools were used to analyze the prognostic information of the seven hub genes. High expression of ADAMTS2, COL10A1, COL1A1, COL1A2, COL8A1, and BGN had a significantly worse survival rate ($P < 0.05$).

TABLE 6: The prognostic information of the seven key candidate genes.

| Category | Genes | | | | | |
|--|---------|---------|--------|--------|--------|-----|
| Genes with significantly worse survival ($P < 0.05$) | ADAMTS2 | COL10A1 | COL1A1 | COL1A2 | COL8A1 | BGN |
| Genes without significantly survival ($P > 0.05$) | SPP1 | | | | | |




FIGURE 8: Validation of expression levels of ADAMTS2, COL10A1, COL1A1, COL1A2, COL8A1, and BGN in GAC patients. To further validate the expression level in GAC patients, six genes were re-analyzed via immunohistochemistry (a), Western blot (b), and real-time PCR (c) analysis. Representative images of IHC staining were shown. Scale bar, 200 μ m. Real-time PCR data were normalized to GAPDH expression. All six genes were highly expressed in GAC tissue compared to adjacent normal tissue.

patients, including gastric adenocarcinoma [29]. The results and related studies have provided solid evidence to prove the relation between the hub genes along with the enriched pathways and GAC.

Expression and survival analysis have demonstrated that ADAMTS2, COL10A1, COL1A1, COL1A2, COL8A1, and BGN are all highly expressed in GAC and their high expression has a significantly worse survival. Previous studies have also showed that the abnormal expression level of the six hub genes could be indicators of the initiation, progression, and clinical outcome of GAC. Till now, little is known about the exact mechanism of the six genes in GAC initiation and progression. In our study, we have provided more helpful information and direction for the future study of GAC via integrated bioinformatical methods, which would be new perspective and clues for early detection and diagnosis of GAC.

5. Conclusion

Altogether, our bioinformatics analysis study identified six upregulated DEGs (ADAMTS2, COL10A1, COL1A1, COL1A2, COL8A1, and BGN) between gastric adenocarcinoma and normal tissues based on four different microarray datasets. Results showed that these six genes were poor

prognostic markers, which may play key roles in the initiation and progression of GAC. These data presented in this study may provide new perspectives and clues into the early detection and therapeutic targets of GAC. However, more experiments and details are needed to verify the prediction and underlying mechanisms in the near future.

Abbreviations

| | |
|-----------|---|
| GAC: | Gastric adenocarcinoma |
| GEO: | Gene Expression Omnibus |
| DEGs: | Differentially expressed genes |
| PPI: | Protein-protein interaction |
| DAVID: | The Database for Annotation, Visualization and Integrated Discovery |
| GO: | Gene ontology |
| KEGG | Kyoto Encyclopedia of Gene and Genome |
| pathways: | pathways |
| STRING: | Search Tool for the Retrieval of Interacting Genes |
| MCODE: | Molecular Complex Detection |
| GEPIA: | Gene Expression Profiling Interactive Analysis |
| TCGA: | The Cancer Genome Atlas |
| ADAMTS2: | |

| | |
|----------|--|
| | ADAM metallopeptidase with thrombospondin type 1 motif 2 |
| COL10A1: | Collagen type X alpha 1 chain |
| COL1A1: | Collagen type I alpha 1 chain |
| COL1A2: | Collagen type I alpha 2 chain |
| COL8A1: | Collagen type VIII alpha 1 chain |
| BGN: | Biglycan |
| SPP1: | Secreted phosphoprotein 1. |

Data Availability

The dataset supporting our findings is available at the following website: <https://www.ncbi.nlm.nih.gov/geo/>. All data generated or analyzed during this study are available from the corresponding author upon reasonable request.

Ethical Approval

This study was approved by the ethics committee of the General Hospital of Western Theater Command (APPROVAL NUMBER/ID: 2021ky141-1), and informed consent was exempted.

Conflicts of Interest

The authors have declared that there are no conflicts of interest.

Authors' Contributions

Yamei Li and Yan Luo contributed equally to this work.

Acknowledgments

This study was supported by the Key Research and Development Project of Sichuan Province (Grant no. 2022YFS0259, 2022YFS0332) and General Hospital of Western Theater Command (Grant no. 2021-XZYG-C01).

References

- [1] J. A. Ajani, J. Lee, T. Sano, Y. Y. Janjigian, D. Fan, and S. Song, "Gastric adenocarcinoma," *Nature Reviews Disease Primers*, vol. 3, no. 1, p. 17036, 2017.
- [2] L. Li, Z. Zhu, Y. Zhao et al., "FN1, SPARC, and SERPINE1 are highly expressed and significantly related to a poor prognosis of gastric adenocarcinoma revealed by microarray and bioinformatics," *Scientific Reports*, vol. 9, no. 1, p. 7827, 2019.
- [3] H. Sung, J. Ferlay, R. Siegel et al., "Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," *CA: A Cancer Journal for Clinicians*, vol. 71, no. 3, pp. 209–249, 2021.
- [4] K. Fujitani, "Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the east," *Digestive Surgery*, vol. 30, no. 2, pp. 119–129, 2013.
- [5] L. A. Torre, R. L. Siegel, E. M. Ward, and A. Jemal, "Global cancer incidence and mortality rates and trends—an update," *Cancer Epidemiology Biomarkers & Prevention*, vol. 25, no. 1, pp. 16–27, 2016.
- [6] A. Verdecchia, S. Francisci, H. Brenner et al., "Recent cancer survival in Europe: a 2000–02 period analysis of EURO CARE-4 data," *Lancet Oncology*, vol. 8, no. 9, pp. 784–796, 2007.
- [7] W. K. Leung, M. S. Wu, Y. Kakugawa et al., "Screening for gastric cancer in Asia: current evidence and practice," *Lancet Oncology*, vol. 9, no. 3, pp. 279–287, 2008.
- [8] K. D. Crew and A. I. Neugut, "Epidemiology of gastric cancer," *World Journal of Gastroenterology*, vol. 12, no. 3, pp. 354–362, 2006.
- [9] J. A. Ajani, T. A. D'Amico, K. Almhanna et al., "Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology," *Journal of the National Comprehensive Cancer Network*, vol. 14, no. 10, pp. 1286–1312, 2016.
- [10] M. Nair, S. S. Sandhu, and A. K. Sharma, "Cancer molecular markers: a guide to cancer detection and management," *Seminars in Cancer Biology*, vol. 52, pp. 39–55, 2018.
- [11] J. L. Vincent, E. Bogossian, and M. Menozzi, "The future of biomarkers," *Critical Care Clinics*, vol. 36, no. 1, pp. 177–187, 2020.
- [12] J. Zou and E. Wang, "Cancer biomarker discovery for precision medicine: new progress," *Current Medicinal Chemistry*, vol. 26, no. 42, pp. 7655–7671, 2020.
- [13] T. Matsuoka and M. Yashiro, "Biomarkers of gastric cancer: current topics and future perspective," *World Journal of Gastroenterology*, vol. 24, no. 26, pp. 2818–2832, 2018.
- [14] M. Kanda and Y. Kodera, "Recent advances in the molecular diagnostics of gastric cancer," *World Journal of Gastroenterology*, vol. 21, no. 34, pp. 9838–9852, 2015.
- [15] C. Duraes, G. M. Almeida, R. Seruca, C. Oliveira, and F. Carneiro, "Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?" *Virchows Archiv*, vol. 464, no. 3, pp. 367–378, 2014.
- [16] H. Feng, Z.-Y. Gu, Q. Li, Q.-H. Liu, X.-Y. Yang, and J.-J. Zhang, "Identification of significant genes with poor prognosis in ovarian cancer via bioinformatical analysis," *Journal of Ovarian Research*, vol. 12, no. 1, p. 35, 2019.
- [17] M. Lu, X. Fan, W. Liao et al., "Identification of significant genes as prognostic markers and potential tumor suppressors in lung adenocarcinoma via bioinformatical analysis," *BMC Cancer*, vol. 21, no. 1, p. 616, 2021.
- [18] S. Davis and P. S. Meltzer, "GEOquery: a bridge between the gene expression omnibus (GEO) and bioconductor," *Bioinformatics*, vol. 23, no. 14, pp. 1846–1847, 2007.
- [19] D. W. Huang, B. T. Sherman, and R. A. Lempicki, "Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources," *Nature Protocols*, vol. 4, no. 1, pp. 44–57, 2009.
- [20] M. Ashburner, C. A. Ball, J. A. Blake et al., "Gene ontology: tool for the unification of biology," *Nature Genetics*, vol. 25, no. 1, pp. 25–29, 2000.
- [21] M. Kanehisa and S. Goto, "KEGG: kyoto encyclopedia of genes and genomes," *Nucleic Acids Research*, vol. 28, no. 1, pp. 27–30, 2000.
- [22] D. Szklarczyk, A. Franceschini, S. Wyder et al., "STRING v10: protein-protein interaction networks, integrated over the tree of life," *Nucleic Acids Research*, vol. 43, pp. D447–D452, 2015.
- [23] P. Shannon, A. Markiel, O. Ozier et al., "Cytoscape: a software environment for integrated models of biomolecular interaction networks," *Genome Research*, vol. 13, no. 11, pp. 2498–2504, 2003.
- [24] A. Nagy, A. Lanczky, O. Menyhart, and B. Gyorfy, "Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets," *Scientific Reports*, vol. 8, no. 1, p. 9227, 2018.

- [25] Z. Tang, C. Li, B. Kang, G. Gao, C. Li, and Z. Zhang, "GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses," *Nucleic Acids Research*, vol. 45, pp. W98–W102, 2017.
- [26] B. T. Hennessy, D. L. Smith, P. T. Ram, Y. Lu, and G. B. Mills, "Exploiting the PI3K/AKT pathway for cancer drug discovery," *Nature Reviews Drug Discovery*, vol. 4, no. 12, pp. 988–1004, 2005.
- [27] C. Jiang, Y. Zhou, Y. Huang, Y. Wang, W. Wang, and X. Kuai, "Overexpression of ADAMTS-2 in tumor cells and stroma is predictive of poor clinical prognosis in gastric cancer," *Human Pathology*, vol. 84, pp. 44–51, 2019.
- [28] T. J. Mead and S. S. Apte, "ADAMTS proteins in human disorders," *Matrix Biology*, vol. 71-72, pp. 225–239, 2018.
- [29] S. F. Zhao, X. J. Yin, W. J. Zhao, L. C. Liu, and Z. P. Wang, "Biglycan as a potential diagnostic and prognostic biomarker in multiple human cancers," *Oncology Letters*, vol. 19, no. 3, pp. 1673–1682, 2020.